达格列净致扩张型心肌病并慢性心力衰竭患者异常子宫出血 1 例报告。
Dapagliflozin-induced abnormal uterine bleeding in a patient with dilated cardiomyopathy and chronic heart failure: a case report.
机构信息
Department of Cardiovascular, Beilun District People's Hospital (Zhejiang University School of Medicine First Affiliated Hospital Beilun Branch), Ningbo, Zhejiang 315800, China.
Department of Pharmacy, Beilun District People's Hospital (Zhejiang University School of Medicine First Affiliated Hospital Beilun Branch), Ningbo, Zhejiang 315800, China.
出版信息
J Int Med Res. 2024 Aug;52(8):3000605241271750. doi: 10.1177/03000605241271750.
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are extensively used in the management of heart failure because of their cardiovascular benefits. Adverse drug reactions associated with dapagliflozin include diabetic ketoacidosis, fungal infections, and increased blood glucose concentrations. However, abnormal uterine bleeding is not a known side effect of dapagliflozin. We report a 75-year-old Chinese woman with dilated cardiomyopathy and chronic heart failure who experienced abnormal uterine bleeding while taking dapagliflozin. Notably, cessation of dapagliflozin administration resulted in the disappearance of uterine bleeding. These findings suggest that dapagliflozin possesses additional potential mechanisms, but these mechanisms require further investigation. Furthermore, healthcare professionals should remain vigilant regarding the occurrence of uterine bleeding when prescribing dapagliflozin.
钠-葡萄糖协同转运蛋白 2（SGLT2）抑制剂由于其心血管益处，被广泛用于心力衰竭的治疗。达格列净相关的药物不良反应包括糖尿病酮症酸中毒、真菌感染和血糖浓度升高。然而，异常子宫出血并不是达格列净的已知副作用。我们报告了一例 75 岁的中国女性，患有扩张型心肌病和慢性心力衰竭，在服用达格列净时出现异常子宫出血。值得注意的是，停止达格列净治疗后，子宫出血消失。这些发现表明，达格列净具有其他潜在的机制，但这些机制需要进一步研究。此外，当开具达格列净处方时，医疗保健专业人员应警惕子宫出血的发生。
Zotero 插件